Literature DB >> 19546558

Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after Yttrium-90 radioembolization with resin microspheres or after CT-guided high-dose-rate brachytherapy.

Ricarda Rühl1, Max Seidensticker, Nils Peters, Konrad Mohnike, Jan Bornschein, Kerstin Schütte, Holger Amthauer, Peter Malfertheiner, Maciej Pech, Jens Ricke.   

Abstract

PURPOSE: To identify changes of liver function after single-fraction irradiation or yttrium-90 radioembolization ((90)Y-RE) of hepatocellular carcinoma associated with liver cirrhosis on the basis of laboratory data. METHODS AND MATERIALS: 24 patients with primary liver carcinoma and liver cirrhosis classified Child-Pugh A or B were treated either by image-guided high-dose-rate brachytherapy (HDR-BT) (12 patients) or by (90)Y-RE (12 patients). The following laboratory parameters were assessed 1 day before and 3 days, 6 weeks and 3 months after the intervention: total bilirubin and gamma-glutamyl transpeptidase (GGTP) as parameters of detoxification function, albumin and cholinesterase (ChE) as direct synthesis parameters, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) as indicators of liver tissue damage. Preinterventional values were taken as baseline, following values were calculated as percentage changes from the baseline value. Statistical analysis was performed using the Wilcoxon-matched pairs test, comparing postinterventional with preinterventional values. Differences were considered statistically significant with a p value <0.05.
RESULTS: In all patients the median bilirubin, ALT, AP and albumin values remained within normal limits at any time of follow-up. AST levels in the RE group and GGTP in both groups have been already elevated over a normal range before the intervention, and in both groups both parameters showed a slight increase after interventions. ChE activity was lowered already in the baseline values and showed a further decrease 3 days after BT as well as 3 days and 6 weeks after RE, with final reconstitution to baseline values. All liver function test parameters showed mild changes shortly after radiation therapy but floating laboratory values recovering within 12 weeks to baseline values. Radiation or RE-induced liver disease was recorded in no patient.
CONCLUSIONS: Liver function parameters show only mild changes shortly after intervention with recovery within 6-12 weeks to baseline values. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546558     DOI: 10.1159/000218352

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  7 in total

1.  Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.

Authors:  K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

2.  Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy.

Authors:  Frederic Carsten Schmeel; Birgit Simon; Amir Sabet; Julian Alexander Luetkens; Frank Träber; Leonard Christopher Schmeel; Samer Ezziddin; Hans Heinz Schild; Dariusch Reza Hadizadeh
Journal:  Eur Radiol       Date:  2016-06-07       Impact factor: 5.315

3.  Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.

Authors:  Frederic Carsten Schmeel; Birgit Simon; Julian Alexander Luetkens; Frank Träber; Carsten Meyer; Leonard Christopher Schmeel; Amir Sabet; Samer Ezziddin; Hans Heinz Schild; Dariusch Reza Hadizadeh
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-19       Impact factor: 4.553

4.  Radioablation of liver malignancies with interstitial high-dose-rate brachytherapy : Complications and risk factors.

Authors:  Konrad Mohnike; Steffen Wolf; Robert Damm; Max Seidensticker; Ricarda Seidensticker; Frank Fischbach; Nils Peters; Peter Hass; Günther Gademann; Maciej Pech; Jens Ricke
Journal:  Strahlenther Onkol       Date:  2016-02-29       Impact factor: 3.621

5.  Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.

Authors:  Matthew Walton; Ros Wade; Lindsay Claxton; Sahar Sharif-Hurst; Melissa Harden; Jai Patel; Ian Rowe; Robert Hodgson; Alison Eastwood
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

6.  Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes.

Authors:  Max Seidensticker; Ricarda Seidensticker; Konrad Mohnike; Christian Wybranski; Thomas Kalinski; Sebastian Luess; Maciej Pech; Peter Wust; Jens Ricke
Journal:  Radiat Oncol       Date:  2011-04-17       Impact factor: 3.481

Review 7.  Morphological and functional MDCT: problem-solving tool and surrogate biomarker for hepatic disease clinical care and drug discovery in the era of personalized medicine.

Authors:  Liang Wang
Journal:  Hepat Med       Date:  2010-08-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.